EVG.L Share News (EVG)

EVG.L Information

There is currently no data for EVG

Richard Moulson to join Evgen Pharma as CFO

Tue, 17th Jan 2017 12:35

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday.The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 February 2017, on which date the current CFO John Bradshaw will leave the company to focus on his work with a new healthcare investment vehicle.Moulson will then join the company's board and become CFO on 1 March.He graduated in zoology at Exeter University before qualifying as an accountant at Coopers & Lybrand.Moulson worked in corporate finance at Deutsche Morgan Grenfell for 10 years before working in financial and company secretarial roles at a number of UK biotechnology and technology companies.Since 2012, he has had a portfolio of interests, including recently as CFO of Cogent Breeding and previously as interim CFO at both ReNeuron Group and Enigma Diagnostics.Evgen also announced that David Howat, who holds the non-board position of chief development officer, will leave the company at the end of March.Howat led the preclinical and early-stage clinical development of the company's lead product - SFX-01 - through to the Phase II trials.The Phase II trials will continue to be managed by senior clinical study manager Dave Chadwick, who will assumes the non-board position of head of clinical operations on 1 March."On behalf of the board, I would like to express our sincere thanks to John Bradshaw for his valuable contribution to the development of Evgen Pharma, including his important role in the Company's IPO," said CEO Stephen Franklin."I would like to welcome Richard Moulson to Evgen Pharma," he continued."Richard is an experienced CFO with a track record in life sciences and we all look forward to his input to the company and to the board".Dr Franklin also thanked Howat for being a "tremendous asset" during Evgen's formative years and helping to take its lead product through to the current patient trials."David leaves us to join an earlier-stage company and the board extends its thanks and wishes him every success in his new role."

More News

27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Latest Share Chat

EVG.L Share News (EVG)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Richard Moulson to join Evgen Pharma as CFO

Login to your account

Quickpicks are a member only feature

Login to your account